Search research articles
Contact Us
Filters
Showing results (141-150 of 181) with videos related to
Page
of 19
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica
|
April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
Journal of the International AIDS Society
|
November 15, 2014
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
Daniel Podzamczer, Nerea Rozas, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]
Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2011
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
Marylène Lejeune, José M Miró, Elisa De Lazzari, et al.
The New England Journal of Medicine
|
September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
Esteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 13, 2014
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial
Esteban Martinez, Ana Gonzalez-Cordon, Elena Ferrer, et al.
The Lancet. HIV
|
March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Current HIV Research
|
October 16, 2012
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
Daniel Podzamczer, Esteban Martínez, Pere Domingo, et al.
Plos One
|
October 12, 2016
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Jesús Troya, Pablo Ryan, Esteban Ribera, et al.
Plos One
|
February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Jesús Troya, Pablo Ryan, Esteban Ribera, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 181) with videos related to
Sort By:
Page
of 19
Enfermedades Infecciosas Y Microbiologia Clinica
|
April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]
Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
Journal of the International AIDS Society
|
November 15, 2014
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
Daniel Podzamczer, Nerea Rozas, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]
Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2011
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
Marylène Lejeune, José M Miró, Elisa De Lazzari, et al.
The New England Journal of Medicine
|
September 12, 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
Esteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 13, 2014
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial
Esteban Martinez, Ana Gonzalez-Cordon, Elena Ferrer, et al.
The Lancet. HIV
|
March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Current HIV Research
|
October 16, 2012
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
Daniel Podzamczer, Esteban Martínez, Pere Domingo, et al.
Plos One
|
October 12, 2016
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Jesús Troya, Pablo Ryan, Esteban Ribera, et al.
Plos One
|
February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Jesús Troya, Pablo Ryan, Esteban Ribera, et al.
Page
of 19